-
IRAK Related Products (43)
Related Products (43)
-
JH-X-119-01 (Standard)
0 ImagesCat. No.: HY-103017ARCAS No.: 2227368-54-7JH-X-119-01 (Standard) is the analytical standard of JH-X-119-01 (HY-103017A). This product is intended for research and analytical applications. JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM.
-
IRAK4-IN-7 (Standard)
0 ImagesCat. No.: HY-109585RCAS No.: 1801343-74-7IRAK4-IN-7 (Standard) is the analytical standard of IRAK4-IN-7 (HY-109585). This product is intended for research and analytical applications. IRAK4-IN-7 is a selective, potent and orally active interleuKin-1 receptor-associated Kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment.
-
Emavusertib mesylate
0 ImagesCat. No.: HY-135317DCAS No.: 2376399-40-3Synonyms: CA-4948 mesylateEmavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib (HY-135317). Emavusertib mesylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib mesylate exhibits antitumor activity in mouse model.
